The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). …

Friedreich AtaxiaCardiomyopathiesCardiac Hypertrophy+1 more

~Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT05302271

Phase 2

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease: A Prospective, Phase II Study.

This study is a pilot, phase II, open-label study of the angiotensin II receptor blocker, losartan, in patients with Sickle Cell Disease (SCD) 6 years or older…

Sickle Cell DiseaseDiffuse Myocardial Fibrosis

~Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT05012631

Phase 4

High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years …

Myocardial Fibrosis

~Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT05954559